Human Endometrial Epithelial Cells Modulate the Activation of Gelatinase A by Stromal CellsGoffin F.a,b · Frankenne F.a · Béliard A.a · Perrier d’Hauterive S.b,c · Pignon M.-R.a · Geenen V.c · Foidart J.-M.a,b
Departments of aTumor and Developmental Biology, bObstetrics and Gynecology, and cMedicine, Center of Immunology, University of Liège, Belgium
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Metalloproteinases (MMPs) are central effectors in endometrial physiology. Their production is tightly regulated by ovarian steroids and cytokines. Using zymography, we investigated MMP-2 production by human endometrial cells treated with estradiol-17β + progesterone (E2+P) and by various key cytokines in endometrial physiology (IL-1β, LIF, TGF-β, and TNF-α). No gelatinase activity was detected in the culture media of epithelial cells. In basal conditions, stromal cells produced the pro form of MMP-2. MMP-2 production/activation was not directly affected by cytokine treatment. Interestingly, activated MMP-2 was only detected after treatment of stromal cells with culture medium from epithelial cells. Cytokine treatment of epithelial cells increased the capacity of conditioned medium to stimulate stromal cells to activate MMP-2. As the tissue inhibitor of MMP-2 (TIMP-2) is a regulator of gelatinase A activity, its concentration was measured by ELISA. TIMP-2 production by stromal cells was not affected by cytokines or by epithelial cell-conditioned medium. These results strongly suggest that regulation of stromal MMP-2 activation involves soluble factor(s) derived from the epithelial compartment.
© 2002 S. Karger AG, Basel
- Noyes RW, Hertig AT, Rock J: Dating the endometrial biopsy. Am J Obstet Gynecol 1975;122:262–263.
- Aplin JD, Charlton AK, Ayad S: An immunohistochemical study of human endometrial extracellular matrix duing the menstrual cycle and first trimester of pregnancy. Cell Tissue Res 1988;253:231–240.
- Nagase H, Barrett AJ, Woessner JF, Jr: Nomenclature and glossary of the matrix metalloproteinases. Matrix Suppl 1992;1:421–424.
- Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151–160.
- Murphy G, Stanton H, Cowell S, et al: Mechanisms for pro matrix metalloproteinase activation. APMIS 1999;107:38–44.
- Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74:111–122.
- Shapiro SD: Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr Opin Cell Biol 1998;10:602–608.
- Rodgers WH, Matrisian LM, Giudice LC, et al: Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 1994;94:946–953.
- Hulboy DL, Rudolph LA, Matrisian LM: Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 1997;3:27–45.
- Singer CF, Marbaix E, Lemoine P, Courtoy PJ, Eeckhout Y: Local cytokines induce differential expression of matrix metalloproteinases but not their tissue inhibitors in human endometrial fibroblasts. Eur J Biochem 1999;259:40–45.
- Lockwood CJ, Krikun G, Hausknecht VA, Papp C, Schatz F: Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal. Endocrinology 1998;139:4607–4613.
- Salamonsen LA, Butt AR, Hammond FR, Garcia S, Zhang J: Production of endometrial matrix metalloproteinases, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab 1997;82:1409–1415.
Osteen KG, Keller NR, Feltus FA, Melner MH: Paracrine regulation of matrix metalloproteinase expression in the normal human endometrium. Gynecol Obstet Invest 1999;48(suppl 1):2–13.
- Rawdanowicz TJ, Hampton AL, Nagase H, Woolley DE, Salamonsen LA: Matrix metalloproteinase production by cultured human endometrial stromal cells: identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha. J Clin Endocrinol Metab 1994;79:530–536.
- Bruner KL, Rodgers WH, Gold LI, et al: Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 1995;92:7362–7366.
- Huang HY, Wen Y, Irwin JC, Kruessel JS, Soong YK, Polan ML: Cytokine-mediated regulation of 92-kilodalton type IV collagenase, tissue inhibitor or metalloproteinase-1 (TIMP-1), and TIMP-3 messenger ribonucleic acid expression in human endometrial stromal cells. J Clin Endocrinol Metab 1998;83:1721–1729.
Bischof P, Martelli M, Campana A, Itoh Y, Ogata Y, Nagase H: Importance of matrix metalloproteinases in human trophoblast invasion. Early Pregnancy 1995;1:263–269.
- Bischof P, Haenggeli L, Campana A: Effect of leukemia inhibitory factor on human cytotrophoblast differentiation along the invasive pathway. Am J Reprod Immunol 1995;34:225–230.
- Schatz F, Krikun G, Runic R, Wang EY, Hausknecht V, Lockwood CJ: Implications of decidualization-associated protease expression in implantation and menstruation. Semin Reprod Endocrinol 1999;17:3–12.
- Zhang J, Hampton AL, Nie G, Salamonsen LA: Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: Enzymes coordinately expressed in human endometrium. Biol Reprod 2000;62:85–94.
- Matrisian LM: Matrix metalloproteinase gene expression. Ann NY Acad Sci 1994;732:42–50.
- Irwin JC, Kirk D, Gwatkin RB, Navre M, Cannon P, Giudice LC: Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase. Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle. J Clin Invest 1996;97:438–447.
- Stetler-Stevenson WG: Progelatinase A activation during tumor cell invasion. Invasion Metastasis 1994;14:259–268.
- Deryugina EI, Luo GX, Reisfeld RA, Bourdon MA, Strongin A: Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 1997;17:3201–3210.
- Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270:5331–5338.
- Schatz F, Papp C, Toth-Pal E, et al: Protease and protease inhibitor expression during in vitro decidualization of human endometrial stromal cells. Ann NY Acad Sci 1994;734:33–42.
- Wenzl RJ, Heinzl H: Localization of matrix metalloproteinase-2 in uterine endometrium and ectopic implants. Gynecol Obstet Invest 1998;45:253–257.
- Polette M, Nawrocki B, Pintiaux A, et al: Expression of gelatinases A and B and their tissue inhibitors by cells of early and term human placenta and gestational endometrium. Lab Invest 1994;71:838–846.
- Bjorn SF, Hastrup N, Lund LR, Dano K, Larsen JF, Pyke C: Co-ordinated expression of MMP-2 and its putative activator, MT1-MMP, in human placentation. Mol Hum Reprod 1997;3:713–723.
- Tseng L, Zhu HH: Progestin, estrogen, and insulin-like growth factor-I stimulate the prolactin receptor mRNA in human endometrial stromal cells. J Soc Gynecol Invest 1998;5:149–155.
- Martelli M, Campana A, Bischof P: Secretion of matrix metalloproteinases by human endometrial cells in vitro. J Reprod Fertil 1993;98:67–76.
- Laird SM, Li TC, Bolton AE: The production of placental protein 14 and interleukin 6 by human endometrial cells in culture. Hum Reprod 1993;8:793–798.
- Remacle AG, Baramova EN, Weidle UH, Krell HW, Foidart JM: Purification of progelatinases A and B by continuous-elution electrophoresis. Protein Expr Purif 1995;6:417–422.
- Remacle A, McCarthy K, Noel A, et al: High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000;89:118–121.
- Singer CF, Marbaix E, Lemoine P, Eeckhout Y, Courtoy PJ: Interleukin-1 receptor-ligand interactions modulate interstitial collagenase-1 production by human endometrial fibroblasts. Mol Hum Reprod 1999;5:240–245.
- Ellenrieder V, Alber B, Lacher U, et al: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000;85:14–20.
- Soini Y, Alarakkola E, Autio-Harmainen H: Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 1997;28:220–226.
- Salamonsen LA: Matrix metalloproteinases and endometrial remodelling. Cell Biol Int 1994;18:1139–1144.
Salamonsen LA, Woolley DE: Matrix metalloproteinases in normal menstruation. Hum Reprod 1996;11(suppl 2):124–133.
- Nagase H, Suzuki K, Itoh Y, et al: Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Adv Exp Med Biol 1996;389:23–31.
- Seiki M: Membrane-type matrix metalloproteinases. APMIS 1999;107:137–143.
- Ornstein DL, MacNab J, Cohn KH: Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer. Clin Exp Metastasis 1999;17:205–212.
- Polette M, Gilles C, Marchand V, Seiki M, Tournier JM, Birembaut P: Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells. Clin Exp Metastasis 1997;15:157–163.
- Corcoran ML, Hewitt RE, Kleiner DE Jr, Stetler-Stevenson WG: MMP-2: Expression, activation and inhibition. Enzyme Protein 1996;49:7–19.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.